Allogene Therapeutics (NASDAQ:ALLO) Stock Rating Upgraded by Citizens Jmp
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) was upgraded by research analysts at Citizens Jmp from a “market perform” rating to an “outperform” rating in a research report issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $5.00 price target on the stock. Citizens Jmp’s price target would indicate a potential upside of […]
